-
Environmental Science and Pollution... Jun 2022A novel Ag/BiOBr/CeO composite was successfully prepared for the first time, which had excellent performance in degrading sulfisoxazole (SSX) under visible light...
A novel Ag/BiOBr/CeO composite was successfully prepared for the first time, which had excellent performance in degrading sulfisoxazole (SSX) under visible light irradiation. The as-prepared samples were characterized by SEM, XRD, UV-vis DRS and BET et al. The composite of 10% Ag/BiOBr/CeO showed the best photocatalytic activity and more than 99.5% SSX can be removed within 20 min. It exhibited the highest k value of 0.2428 min, which was about 39.7 times higher than pure BiOBr (6.11 × 10 min) and 22.1 times higher than BiOBr/CeO (1.09 × 10 min), respectively. The addition of Ag significantly improved the absorption rate of visible light and the separation rate of photogenerated electron-hole pairs. The initial pH and dosage of samples could have an influence on the photocatalytic activity. The radical trapping experiments proved that ·O and h were the main active species involved in photocatalytic degradation. Finally, the synthesized catalyst maintained excellent photocatalytic activity after 5 repeated cycles, which indicated the extraordinary stability and recyclability of Ag/BiOBr/CeO.
Topics: Bismuth; Catalysis; Light; Sulfisoxazole
PubMed: 35167019
DOI: 10.1007/s11356-021-17669-y -
Molecules (Basel, Switzerland) Mar 2022In this work, new electrochemical sensors based on the modification of glassy carbon electrode (GCE) with multiwalled carbon nanotubes (MWCNTs)-rare metal oxides (REMO)...
In this work, new electrochemical sensors based on the modification of glassy carbon electrode (GCE) with multiwalled carbon nanotubes (MWCNTs)-rare metal oxides (REMO) nanocomposites were fabricated by drop-to-drop method of MWCNTs-REMO dispersion in ethanol. REMO nanoparticles were synthesized by precipitation followed by hydrothermal treatment at 180 °C in absence and presence of Triton X-100 surfactant. Cyclic voltammetry (CV) analysis using MWCNTs-CeO@GCE and MWCNTs-YbO@GCE sensors were used for the analysis of sulfisoxazole (SFX) drug in water samples. The results of CV analysis showed that MWCNTs-REMO@GCE sensors have up to 40-fold higher sensitivity with CeO compared to the bare GCE sensor. The estimated values of the limit of detection (LoD) of this electrochemical sensing using MWCNTs-CeO@GCE and MWCNTs-YbO@GCE electrodes reached 0.4 and 0.7 μM SFX in phosphate buffer pH = 7, respectively. These findings indicate that MWCNTs-REMO@GCE electrodes are potential sensors for analysis of sulfonamide drugs in water and biological samples.
Topics: Electrochemical Techniques; Electrodes; Nanotubes, Carbon; Oxides; Phosphates; Sulfisoxazole
PubMed: 35335394
DOI: 10.3390/molecules27062033 -
Medical Technicians Bulletin 1953
Topics: Sulfanilamide; Sulfanilamides; Sulfisoxazole; Sulfonamides
PubMed: 13098644
DOI: No ID Found -
Ceskoslovenska Farmacie Dec 1966
Topics: Chemistry, Pharmaceutical; Sulfisoxazole
PubMed: 5980762
DOI: No ID Found -
JAMA Jun 1978During treatment of brucellosis with sulfisoxazole, tetracycline, and streptomycin sulfate, severe thrombocytopenic purpura developed in a young farmer. Verification for...
During treatment of brucellosis with sulfisoxazole, tetracycline, and streptomycin sulfate, severe thrombocytopenic purpura developed in a young farmer. Verification for an immune mechanism was provided by clinical challenge with a small dose of sulfisoxazole that caused recurrence of thrombocytopenia and by serologic laboratory test results that detected a serum factor causing platelet agglutination requiring the presence of sulfisoxazole. The original antigenic stimulation was considered to come from drinking cows' milk contaminated with sulfonamide drugs. Cross-reactivity with some other sulfonamide drugs was demonstrated.
Topics: Adult; Animals; Blood Platelets; Brucellosis; Cross Reactions; Drug Hypersensitivity; Humans; Male; Milk; Purpura, Thrombocytopenic; Sulfisoxazole
PubMed: 580789
DOI: 10.1001/jama.239.24.2586 -
Journal of Pharmaceutical and... Sep 2016N(1)-acetyl sulfisoxazole (N1AS), a dihydropteroate synthase inhibitor is known to be biotransformed primarily to sulfisoxazole, partly to N(4)-acetyl sulfisoxazole... (Comparative Study)
Comparative Study
N(1)-acetyl sulfisoxazole (N1AS), a dihydropteroate synthase inhibitor is known to be biotransformed primarily to sulfisoxazole, partly to N(4)-acetyl sulfisoxazole (N4AS), and likely also to diacetyl sulfisoxazole (DAS) and other compounds. Although its clinical use has been limited due to urolithiasis, some countries still use the drug in combination with trimethoprim in cattle. A liquid chromatographic method using ultraviolet detection was developed for the simultaneous determination of four substances for the first time. Four analytes and sulfamethoxazole (IS) were separated on a reversed-phase column with gradient elution of a mobile phase. Because DAS and N1AS in plasma were changed very quickly into N4AS and sulfisoxazole, respectively, and esterase inhibitors (sodium fluoride and eserine) could not prevent the transformation, sulfisoxazole and N4AS were monitored in rat plasma following a single oral administration of N1AS and sulfisoxazole in five rats. The relative bioavailability of N1AS to sulfisoxazole was about two, indicating that a half-dose of N1AS would be equivalent to a dose of sulfisoxazole to achieve the same systemic exposure to sulfisoxazole.
Topics: Administration, Oral; Animals; Biological Availability; Chromatography, High Pressure Liquid; Rats; Rats, Sprague-Dawley; Sulfisoxazole
PubMed: 27423008
DOI: 10.1016/j.jpba.2016.06.055 -
Pediatrics Apr 1983Sulfisoxazole, 75 mg/kg/d in two divided doses for 3 months, was administered in a double-blind placebo crossover study to 35 children aged 6 months to 5 years who had... (Clinical Trial)
Clinical Trial Comparative Study Randomized Controlled Trial
Sulfisoxazole, 75 mg/kg/d in two divided doses for 3 months, was administered in a double-blind placebo crossover study to 35 children aged 6 months to 5 years who had frequent recurring episodes of otitis media. There was a 40% reduction in the rate of otitis media among patients receiving sulfisoxazole compared with those receiving placebo (0.25 v 0.42 episode per patient-month) which did not depend on age, sex, season, or several other factors. Using a randomized order, among patients who received placebo first, there was a 64% reduction on sulfisoxazole therapy compared with placebo (0.20 v 0.56 episode per patient-month). In this subgroup, there was significant improvement in eustachian tube function according to serial tympanograms. In the patients who received sulfisoxazole first, the rate of acute otitis remained low on placebo (0.28 v 0.30 episode per patient-month), and tympanogram patterns continued to improve after discontinuation of the active drug. These differences suggest a carry-over effect from the benefits of chemoprophylaxis. There was no significant difference in the species or sensitivity patterns of bacteria isolated from patients receiving sulisoxazole or placebo. Sulfisoxazole chemoprophylaxis appears to be safe and effective in significantly reducing episodes of otitis media and improving tympanogram patterns.
Topics: Acoustic Impedance Tests; Child, Preschool; Double-Blind Method; Eustachian Tube; Female; Haemophilus influenzae; Humans; Infant; Male; Otitis Media; Random Allocation; Recurrence; Streptococcus pneumoniae; Sulfisoxazole
PubMed: 6601256
DOI: No ID Found -
American Journal of Diseases of... Jun 1985The efficacy of sulfisoxazole prophylaxis was evaluated in 32 otitis-prone children in a double-blind cross-over clinical trial. During the sulfisoxazole therapy, seven... (Clinical Trial)
Clinical Trial
The efficacy of sulfisoxazole prophylaxis was evaluated in 32 otitis-prone children in a double-blind cross-over clinical trial. During the sulfisoxazole therapy, seven patients (22%) had nine episodes of acute otitis media (AOM) while 20 patients (63%) receiving placebo had 36 episodes of AOM (P = .001). Although sulfisoxazole appeared to be beneficial in patients aged 2 to 5 years, statistically significant efficacy was noted only in children under 2 years of age. Otitis media with effusion persisting for more than five weeks was observed in ten children (31%) during sulfisoxazole therapy and in 14 children (44%) during the placebo period (P greater than .975). Sulfisoxazole therefore appears effective in preventing recurrent symptomatic AOM but not in reducing the frequency of persistent otitis media with effusion. The importance of careful follow-up of children receiving long-term sulfisoxazole therapy for prevention of recurrent AOM is stressed.
Topics: Acute Disease; Child, Preschool; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Infant; Male; Otitis Media; Otitis Media with Effusion; Recurrence; Sulfisoxazole
PubMed: 3890523
DOI: 10.1001/archpedi.1985.02140080102044 -
Archives of Ophthalmology (Chicago,... Apr 1981A 35-year-old man demonstrated sulfisoxazole diolamine-induced photosensitivity during treatment for staphylococcal blepharitis. This reaction was easily avoided by...
A 35-year-old man demonstrated sulfisoxazole diolamine-induced photosensitivity during treatment for staphylococcal blepharitis. This reaction was easily avoided by applying the ointment at bedtime and covering the eyelids during sun-bathing while in therapy. A drug-induced photosensitivity reaction should be considered in cases of staphylococcal blepharitis resistant to or aggravated by eyelid-margin therapy with sulfonamides.
Topics: Adult; Blepharitis; Eyelid Diseases; Humans; Male; Photosensitivity Disorders; Staphylococcal Infections; Sulfisoxazole
PubMed: 7224931
DOI: 10.1001/archopht.1981.03930010609004 -
British Medical Journal May 1968
Topics: Anti-Infective Agents; Drug Synergism; Folic Acid Antagonists; Humans; Pyrimidines; Sulfamethoxazole; Sulfisoxazole
PubMed: 5648994
DOI: No ID Found